Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Anat Histol Embryol ; 44(6): 460-7, 2015 Dec.
Article in English | MEDLINE | ID: mdl-25376527

ABSTRACT

Liver anatomy, particularly its vascularization, has been investigated in many studies in dogs. Knowledge of blood flow from the main tributaries of the portal vein (PV) is necessary to explain the preferential sites of secondary lesions within the liver based on the site of the initial malignant lesion. How these flows come together was established in an earlier ex vivo study. Here, we highlight in vivo the blood flows from the main PV tributaries and their distribution in the liver of normal dogs. Portographs of the main PV tributaries were obtained in seven dogs after injection of an angiographic contrast medium. After euthanasia, the livers and their portal vascularization (PV and tributaries) were extracted for a comparative corrosion cast study. Flows were demonstrated in the cranial mesenteric vein, caudal mesenteric vein and splenic vein. However, no proper flow could be distinguished for the gastroduodenal and ileocolic veins. All these tributaries primarily supply the lateral liver lobes (right or left). Most of our observations indicate that the cranial mesenteric, caudal mesenteric and splenic veins primarily supply the right lateral lobe and the caudate process of the caudate lobe and secondarily the left lateral lobe, left medial lobe and the quadrate lobe. The two other tributaries (gastroduodenal and ileocolic veins) primarily supply the right lateral lobe and the caudate process of the caudate lobe.


Subject(s)
Angiography/veterinary , Liver/blood supply , Portal Vein/anatomy & histology , Regional Blood Flow/physiology , Animals , Contrast Media , Dogs , Female , Fluoroscopy/veterinary , Liver/anatomy & histology , Male
2.
Anat Histol Embryol ; 42(5): 355-61, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23293870

ABSTRACT

Most prostatic diseases in dogs are associated with prostatomegaly, and transabdominal ultrasonography has become the imaging modality of choice for evaluation of the prostate gland in the dog. The aim of the present study was to assess the reproducibility, the repeatability and interobserver variations of sonographic measurements of prostate and to determine which measurement had the lowest variability. Length and height of prostate gland were measured on longitudinal views, width of the prostate gland and height of left and right lobes of the gland on transversal views. The within-day and between-day variabilities of the prostatic parameters were determined by performing 1350 (270 length, 270 height, 270 width, 270 height of right lobe and 270 height of left lobe) examinations on ten healthy intact beagle dogs on six different days, in a two-week period (three days for the five dogs, three different days for the five others). Three observers with different levels of experience in ultrasonography performed the examinations. The lowest within-day and between-day standard deviation and coefficient of variation values were observed for the width of the prostate. The width of the gland measured on transverse frozen images seems to be the most reliable measurement for evaluating size of prostate glands in healthy dogs, although the shape, position, outline, and echogenicity of the prostate should also be assessed.


Subject(s)
Dogs/anatomy & histology , Prostate/anatomy & histology , Prostate/diagnostic imaging , Animals , Male , Ultrasonography
3.
Vet Ophthalmol ; 14 Suppl 1: 117-21, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21923834

ABSTRACT

A 10 year-old castrated male Domestic Short-hair cat with a history of chronic bilateral keratitis was referred for assessment of a red, elevated mass involving the left cornea. The rapid growth of the mass, over a month period in combination with pronounced vascularization and invasion of the corneal surface suggested an aggressive inflammatory or neoplastic process. Following keratectomy, the lesion was diagnosed histopathologically as a hemangiosarcoma. The tumor recurred locally within 3 weeks and enucleation was performed. Histopathologic examination of the globe confirmed the diagnosis and did not reveal infiltration of the limbus and conjunctiva. No signs of local recurrence or metastatic disease have been observed 18 months following enucleation. To the authors' knowledge this is the first case of primary corneal hemangiosarcoma described in the feline species.


Subject(s)
Cat Diseases/diagnosis , Cornea/pathology , Eye Neoplasms/veterinary , Hemangiosarcoma/veterinary , Animals , Cat Diseases/pathology , Cat Diseases/surgery , Cats , Cornea/surgery , Eye Neoplasms/diagnosis , Eye Neoplasms/pathology , Eye Neoplasms/surgery , Hemangiosarcoma/diagnosis , Hemangiosarcoma/pathology , Hemangiosarcoma/surgery , Male
4.
Cancer Gene Ther ; 15(7): 456-64, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18340357

ABSTRACT

Ovarian cancers are very aggressive cancers most often diagnosed when metastasis has already occurred in the entire peritoneal cavity. Ovarian adenocarcinoma cells present an undetectable level of RhoB GTPase. Using preclinical ovarian cancer models, we aimed to evaluate the potential use of RhoB cDNA as a tumor suppressor gene in gene therapy. RhoB restoration in vitro, through recombinant adenovirus transduction, resulted in the apoptosis of endogenous RhoB protein low-expressing cell lines (OVCAR-3 and IGROV-1) through the activation of the intrinsic apoptotic caspase cascade. We showed that a single injection of 10(8) p.f.u. of adenoviral vector encoding a reporter gene into the peritoneal cavity of ovarian tumor bearing mice can induce the gene modification of a large quantity of cells throughout the cavity. We thereby tested the effect of AdRhoB injections to treat ovarian cancer-bearing mice. The ectopic expression of RhoB, following its introduction via viral transduction into nude mice in vivo, was highly effective in suppressing tumor growth of ovarian cancer xenografts. Therapeutic agents designed to correct defects of RhoB at the molecular level may thereby provide innovative treatment options for patients not responding to standard therapies.


Subject(s)
Adenocarcinoma/therapy , Gene Expression Regulation, Neoplastic/genetics , Genetic Therapy/methods , Ovarian Neoplasms/therapy , rhoB GTP-Binding Protein/metabolism , Adenocarcinoma/enzymology , Adenoviridae , Animals , Cell Line, Tumor , Female , Genetic Vectors/genetics , Humans , Immunoblotting , Mice , Microscopy, Fluorescence , Ovarian Neoplasms/enzymology , rhoB GTP-Binding Protein/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...